Catalysts for $AMGN
167 tracked
Feb 26, 2021
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Apr 10, 2020
approval
OTEZLA (APREMILAST) โ FDA approval
apremilast
โ
Mar 20, 2020
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Mar 5, 2020
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Mar 5, 2020
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Jul 19, 2019
approval
OTEZLA (APREMILAST) โ FDA approval
apremilast
โ
Jun 13, 2019
approval
AMJEVITA (ADALIMUMAB-ATTO) โ FDA approval
AMJEVITA
โ
Apr 18, 2019
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Apr 18, 2019
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Feb 14, 2019
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Oct 3, 2018
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
May 25, 2018
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
May 25, 2018
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
May 11, 2018
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Apr 10, 2018
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Mar 29, 2018
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Mar 15, 2018
approval
AMJEVITA (ADALIMUMAB-ATTO) โ FDA approval
AMJEVITA
โ
Nov 30, 2017
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Nov 22, 2017
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Oct 6, 2017
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Sep 14, 2017
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Jul 11, 2017
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Jul 11, 2017
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Jun 29, 2017
approval
OTEZLA (APREMILAST) โ FDA approval
apremilast
โ
May 3, 2017
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Nov 4, 2016
approval
ENBREL (ETANERCEPT) โ FDA approval
AMGEN INC
โ
Sep 23, 2016
approval
AMJEVITA (ADALIMUMAB-ATTO) โ FDA approval
AMJEVITA
โ
Aug 30, 2016
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Aug 30, 2016
approval
BLINCYTO (BLINATUMOMAB) โ FDA approval
blinatumomab
โ
Dec 21, 2015
approval
OTEZLA (APREMILAST) โ FDA approval
apremilast
โ